Clinical Trials Logo

Salivary Gland Carcinoma clinical trials

View clinical trials related to Salivary Gland Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05075980 Recruiting - Clinical trials for Head and Neck Carcinoma

HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers

Start date: February 16, 2022
Phase: Phase 2
Study type: Interventional

This clinical trial tests whether intensity modulated proton therapy after surgery works to shrink tumors in patients with head and neck cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors.

NCT ID: NCT03942653 Recruiting - Clinical trials for Salivary Gland Carcinoma

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Start date: May 30, 2019
Phase: Phase 2
Study type: Interventional

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.

NCT ID: NCT03942380 Recruiting - Clinical trials for Head and Neck Cancer

Cell-free Tumor DNA in Head and Neck Cancer Patients

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

This study investigates if head and neck squamous cell carcinoma can be tracked with cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion of cancer, and if it can be used in detecting recurrence in patients already diagnosed and treated for head and neck squamous cell carcinoma.

NCT ID: NCT02628067 Recruiting - Cervical Cancer Clinical Trials

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Start date: December 18, 2015
Phase: Phase 2
Study type: Interventional

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).